Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: A single-center prospective study with historical control

Transfusion

Volumn 55, Issue 8, 2015, Pages 2032-2038

  Martino, Massimo ^a   Moscato, Tiziana ^a   Barillà, Santina ^a   Dattola, Antonia ^a   Pontari, Antonella ^a   Fedele, Roberta ^a   Furlò, Giuseppe ^b   Marzia Stilo, Carmen ^b   Alberto Gallo, Giuseppe ^a   Tripepi, Giovanni ^c  

^a Hematology and Stem Cells Transplantation Unit CTMO CRN Institute of Clinical Physiology   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LENOGRASTIM; PARACETAMOL; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; ARTICLE; BLOOD VOLUME; BODY WEIGHT; BONE PAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; INSOMNIA; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL COUNT; PROSPECTIVE STUDY; SPLENOMEGALY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; ALLOGRAFT; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; HEMATOLOGIC DISEASES; MIDDLE AGED; NEOPLASMS; PAIN; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ALLOGRAFTS; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HISTORICALLY CONTROLLED STUDY; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84938968708     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13117     Document Type: Article

References (26)

1. Appelbaum FR,. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-5.
2. Ljungman P, Bregni M, Brune M, et al., Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-34.
3. Passweg JR, Baldomero H, Peters C, et al., Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014; 49: 744-50
4. Pierelli L, Perseghin P, Marchetti M, et al., Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: Results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion 2012; 52: 893-905
5. Höglund M,. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)-what is the difference? Med Oncol 1998; 15: 229-33.
6. Martin-Christin F,. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 2001; 12: 185-91.
7. Martino M, Console G, Irrera G, et al., Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 2005; 20: 129-36.
8. Fischer JC, Frick M, Wassmuth R, et al., Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740-6.
9. Sourgens H, Lefrère F., A systematic review of available clinical evidence-filgrastim compared with lenograstim. Int J Clin Pharmacol Ther 2011; 49: 510-8
10. Bonig H, Becker PS, Schwebig A, et al., Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? Transfusion 2014; 55: 430-9.
11. Brando B, Barnett D, Janossy G, et al., Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2002; 42: 327-46.
12. Keeney M, Brown W, Gratama J, et al., Single platform enumeration of viable CD34 pos cells. J Biol Regul Homeost Agents 2003; 17: 247-53.
13. Yu J, Leisenring W, Bensinger WI, et al., The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999; 39: 442-50.
14. Martino M, Console G, Dattola A, et al., Short- and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44: 163-8.
15. Martino M, Fedele R, Massara E, et al., Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear? Expert Opin Biol Ther 2012; 12: 609-21.
16. Lemoli RM,. New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis 2012; 4: e2012066.
17. Bertani G, Santoleri L, Martino M, et al., Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study. Transfusion 2014; 54: 2028-3
18. De Haas M, Kerst JM, van der Schoot C, et al., Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effect on circulating neutrophils. Blood 1994; 84: 3885-94.
19. Schwinger W, Mache C, Urban C, et al., Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers. Bone Marrow Transplant 1993; 11: 489-92.
20. Yano T, Katayama Y, Sunami K., G-CSF induced mobilization of peripheral blood stem cells for allografting: comparative study of daily single versus divided dose of G-CSF. Int J Hematol 1997; 66: 169-78.
21. Arbona C, Prosper F, Benet I, et al., Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBSC) in normal donors for allogeneic PBSC transplantation. Bone Marrow Transplant 1998; 22: 39-45.
22. Anderlini P, Donato M, Lauppe MJ, et al., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770-2.
23. Kröger N, Renges H, Krüger W, et al., A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5.
24. Komeno Y, Kanda Y, Hamaki T, et al., A randomized controlled trial to compare once- versus twice-daily filgrastim for mobilization of peripheral blood stem cells from healthy donors. Biol Blood Marrow Transplant 2006; 12: 408-413.
25. Kröger N, Zeller W, Hassan HT, et al., Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Bone Marrow Transplant 1999; 23: 125-9.
26. Kim S, Kim HJ, Park JS, et al., Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742-7.